STOCK TITAN

OKYO Pharma Limited - OKYO STOCK NEWS

Welcome to our dedicated news page for OKYO Pharma (Ticker: OKYO), a resource for investors and traders seeking the latest updates and insights on OKYO Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OKYO Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OKYO Pharma's position in the market.

Rhea-AI Summary
OKYO Pharma Receives FDA Clearance for OK-101 to Treat Neuropathic Corneal Pain, Launches Phase 2 Clinical Trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.58%
Tags
fda approval
-
Rhea-AI Summary
OKYO Pharma Limited (NASDAQ: OKYO) announces the addition of distinguished ophthalmologists to its Scientific Advisory Board following positive safety and efficacy results in its Phase 2 trial of OK-101 for the treatment of dry eye disease and neuropathic corneal pain. The company plans to host a conference call in Q1, 2024 to provide further data on the trial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
management
-
Rhea-AI Summary
OKYO Pharma Limited (OKYO) reports positive safety and efficacy results in its Phase 2 trial for OK-101 ophthalmic solution in subjects with Dry Eye Disease (DED). The trial established a clear path for further development in Phase 3 registration trials. OK-101 demonstrated statistically significant improvements in both signs and symptoms of DED, with a favorable safety profile. The company plans to advance OK-101 into Phase 3 clinical trials, targeting a highly differentiated dry eye product to help underserved patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
clinical trial
Rhea-AI Summary
OKYO Pharma Limited (NASDAQ: OKYO) is presenting at Biotech Showcase in San Francisco to discuss the clinical development status of OK-101, a potential treatment for dry eye disease and neuropathic corneal pain. The company recently completed a phase 2 trial for OK-101, targeting a multi-billion-dollar market for dry eye disease. OKYO Pharma will also be participating in one-on-one partnering meetings at the conference, providing a networking platform for executives and investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.65%
Tags
conferences
-
Rhea-AI Summary
OKYO Pharma Limited (OKYO) announces the completion of the 240-patient phase 2 clinical trial of OK-101 for the treatment of inflammatory dry eye disease (DED) and neuropathic corneal pain. The company is on track to release top-line efficacy and safety data in December 2023. OK-101 has shown promising results in pre-clinical animal studies, and the successful execution of this trial is a crucial step in exploring its potential to treat millions of DED patients in the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
clinical trial
-
Rhea-AI Summary
OKYO Pharma Limited has announced a registered direct offering of 1,092,600 ordinary shares at an offering price of $1.50 per share, resulting in gross cash proceeds of $1.64M. Additionally, the company will extinguish $4.20M of payables by issuing 2,766,667 ordinary shares at the same offering price. This reduction in payables is seen as a significant endorsement of the company's strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
none
Rhea-AI Summary
OKYO Pharma plans to initiate a clinical trial for OK-101 to treat Neuropathic Corneal Pain (NCP). The trial will be led by Dr. Pedram Hamrah and enrollment is planned for Q1 2024. OK-101 is also currently in a Phase 2 clinical trial for dry eye disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.62%
Tags
none
-
Rhea-AI Summary
OKYO Pharma announces positive safety profile for OK-101 in Phase 2 trial for DED treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
clinical trial
-
Rhea-AI Summary
OKYO Pharma closes direct offering of 2.7M shares at $1.50 per share, raising $4.0M for clinical development and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.43%
Tags
offering
Rhea-AI Summary
OKYO Pharma announces pricing of registered direct offering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.61%
Tags
offering
OKYO Pharma Limited

Nasdaq:OKYO

OKYO Rankings

OKYO Stock Data

48.52M
13.64M
25.67%
2.53%
0.32%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Guernsey
Admiral Park